Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 2/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1723184 | 0.84 | KDM4E (0.66) | BACE1KMT2AKDM4EPIM1MMP2 | |
| SCHEMBL18463763 | 0.82 | BACE1 (0.50) | BACE1KMT2AKDM4EPIM1AR | |
| SCHEMBL1726223 | 0.81 | MAPT (0.49) | BACE1KMT2AKDM4EPIM1MMP2 | |
| SCHEMBL16654015 | 0.81 | BACE1 (0.46) | BACE1KMT2AKDM4EPIM1AR | |
| SCHEMBL29496137 | 0.81 | BACE1 (0.46) | BACE1KMT2AKDM4EPIM1AR | |
| SCHEMBL6112866 | 0.80 | PARP1 (0.49) | KMT2AKDM4EPIM1MMP2PARP1 | |
| SCHEMBL1051386 | 0.80 | KDM4E (0.71) | KMT2AKDM4EPIM1MMP2MEN1 | |
| SCHEMBL6594652 | 0.79 | BACE1 (0.47) | BACE1KMT2AKDM4EPIM1AR | |
| SCHEMBL4459171 | 0.79 | KDM4E (0.46) | KMT2AKDM4EPIM1MMP2PARP1 | |
| SCHEMBL28932903 | 0.79 | PARP1 (0.47) | KMT2AKDM4EPIM1MMP2PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12221409-B2 | Method for preparing chiral alkyl compounds by asymmetric hydrogenation of olefins catalyzed by iron complex | ZHEJIANG UNIVERSITY (CN) | 2025-02-11 | — | — | US | disclosed |
| US-20240174588-A1 | METHOD FOR PREPARING CHIRAL ALKYL COMPOUNDS BY ASYMMETRIC HYDROGENATION OF OLEFINS CATALYZED BY IRON COMPLEX | ZHEJIANG UNIVERSITY (CN) | 2024-05-30 | — | — | US | disclosed |
| CN-111747891-B | SNN ligand based on quinoline skeleton, iron complex thereof, preparation method and application | 中国科学院上海有机化学研究所 | 2022-08-09 | — | — | CN | disclosed |
| CN-111747891-A | SNN ligand based on quinoline skeleton, iron complex thereof, preparation method and application | 中国科学院上海有机化学研究所 | 2020-10-09 | — | — | CN | disclosed |
| US-9394297-B2 | Amides as pim inhibitors | AMGEN INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150329538-A1 | AMIDES AS PIM INHIBITORS | AMGEN INC. (US) | 2015-11-19 | — | — | US | disclosed |
| US-20130023634-A1 | CATALYST SYSTEM BASED ON QUINOLINE DONORS | EQUISTAR CHEMICALS, LP | 2013-01-24 | — | — | US | disclosed |
| US-20130023634-A1 | CATALYST SYSTEM BASED ON QUINOLINE DONORS | EQUISTAR CHEMICALS, LP | 2013-01-24 | — | — | US | disclosed |
| US-20120016092-A1 | Catalysts based on quinoline precursors | BASELL POLYOLEFINE GMBH (DE) | 2012-01-19 | — | — | US | disclosed |
| US-20120016092-A1 | Catalysts based on quinoline precursors | BASELL POLYOLEFINE GMBH (DE) | 2012-01-19 | — | — | US | disclosed |
| WO-2012009369-A1 | CATALYSTS BASED ON QUINOLINE PRECURSORS | BASELL POLYOLEFINE GMBG (DE) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174588-A1 | METHOD FOR PREPARING CHIRAL ALKYL COMPOUNDS BY ASYMMETRIC HYDROGENATION OF OLEFINS CATALYZED BY IRON COMPLEX | SFXN1, SFXN3, HMOX2 | BACE1 1341/4885KMT2A 1242/4885KDM4E 2674/4885 |
| US-20150329538-A1 | AMIDES AS PIM INHIBITORS | PIM1, PIM3, PIM2 | BACE1 2404/4885KMT2A 424/4885KDM4E 267/4885 |
| US-12221409-B2 | Method for preparing chiral alkyl compounds by asymmetric hydrogenation of olefins catalyzed by iron complex | SFXN1, SFXN3, HMOX2 | BACE1 1341/4885KMT2A 1242/4885KDM4E 2674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.